Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.

Hansen SN, Ehlers NS, Zhu S, Thomsen MB, Nielsen RL, Liu D, Wang G, Hou Y, Zhang X, Xu X, Bolund L, Yang H, Wang J, Moreira J, Ditzel HJ, Brünner N, Schrohl AS, Stenvang J, Gupta R.

BMC Genomics. 2016 Jun 9;17:442. doi: 10.1186/s12864-016-2749-4.

2.

Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.

Jandu H, Aluzaite K, Fogh L, Thrane SW, Noer JB, Proszek J, Do KN, Hansen SN, Damsgaard B, Nielsen SL, Stougaard M, Knudsen BR, Moreira J, Hamerlik P, Gajjar M, Smid M, Martens J, Foekens J, Pommier Y, Brünner N, Schrohl AS, Stenvang J.

BMC Cancer. 2016 Jan 22;16:34. doi: 10.1186/s12885-016-2071-1.

3.

Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways.

Hansen SN, Westergaard D, Thomsen MB, Vistesen M, Do KN, Fogh L, Belling KC, Wang J, Yang H, Gupta R, Ditzel HJ, Moreira J, Brünner N, Stenvang J, Schrohl AS.

Tumour Biol. 2015 Jun;36(6):4327-38. doi: 10.1007/s13277-015-3072-4. Epub 2015 Jan 18.

PMID:
25596703
4.

Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study.

Thorsen SB, Christensen SL, Würtz SO, Lundberg M, Nielsen BS, Vinther L, Knowles M, Gee N, Fredriksson S, Møller S, Brünner N, Schrohl AS, Stenvang J.

BMC Cancer. 2013 Dec 13;13:598. doi: 10.1186/1471-2407-13-598.

5.

TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells.

Hekmat O, Munk S, Fogh L, Yadav R, Francavilla C, Horn H, Würtz SØ, Schrohl AS, Damsgaard B, Rømer MU, Belling KC, Jensen NF, Gromova I, Bekker-Jensen DB, Moreira JM, Jensen LJ, Gupta R, Lademann U, Brünner N, Olsen JV, Stenvang J.

J Proteome Res. 2013 Sep 6;12(9):4136-51. doi: 10.1021/pr400457u. Epub 2013 Aug 21.

PMID:
23909892
6.

TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.

Bjerre C, Vinther L, Belling KC, Würtz SØ, Yadav R, Lademann U, Rigina O, Do KN, Ditzel HJ, Lykkesfeldt AE, Wang J, Nielsen HB, Brünner N, Gupta R, Schrohl AS, Stenvang J.

Tumour Biol. 2013 Dec;34(6):3839-51. doi: 10.1007/s13277-013-0969-7. Epub 2013 Jul 24.

PMID:
23881388
7.

TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.

Deng X, Fogh L, Lademann U, Jensen V, Stenvang J, Yang H, Brünner N, Schrohl AS.

Tumour Biol. 2013 Apr;34(2):1161-70. doi: 10.1007/s13277-013-0659-5. Epub 2013 Jan 22.

PMID:
23334956
8.

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies.

Schrohl AS, Pedersen HC, Jensen SS, Nielsen SL, Brünner N.

Histopathology. 2011 Nov;59(5):975-83. doi: 10.1111/j.1365-2559.2011.04034.x.

9.
10.

Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.

Klintman M, Ørnbjerg Würtz S, Christensen IJ, Braemer Hertel P, Fernö M, Malmberg M, Mouridsen H, Cold F, Schrohl AS, Foekens JA, Malmström P, Brünner N.

Breast Cancer Res Treat. 2010 Jun;121(2):365-71. doi: 10.1007/s10549-009-0483-1. Epub 2009 Aug 4.

PMID:
19653096
11.

Banking of biological fluids for studies of disease-associated protein biomarkers.

Schrohl AS, Würtz S, Kohn E, Banks RE, Nielsen HJ, Sweep FC, Brünner N.

Mol Cell Proteomics. 2008 Oct;7(10):2061-6. doi: 10.1074/mcp.R800010-MCP200. Epub 2008 Aug 1. Review.

12.

A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.

Schrohl AS, Mueller V, Christensen IJ, Pantel K, Thomssen C, Bruenner N.

Tumour Biol. 2008;29(3):181-7. doi: 10.1159/000146863. Epub 2008 Jul 22.

PMID:
18645261
13.

Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment.

Møller Sørensen N, Vejgaard Sørensen I, Ørnbjerg Würtz S, Schrohl AS, Dowell B, Davis G, Jarle Christensen I, Nielsen HJ, Brünner N.

Scand J Gastroenterol. 2008;43(7):774-86. doi: 10.1080/00365520701878163. Review.

PMID:
18584515
14.

TIMP-1 as a tumor marker in breast cancer--an update.

Würtz SO, Schrohl AS, Mouridsen H, Brünner N.

Acta Oncol. 2008;47(4):580-90. doi: 10.1080/02841860802022976. Review.

PMID:
18465326
15.

Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.

Sørensen NM, Schrohl AS, Jensen V, Christensen IJ, Nielsen HJ, Brünner N.

Scand J Gastroenterol. 2008;43(2):186-91. doi: 10.1080/00365520701491355.

PMID:
18224564
16.
17.

Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.

Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brünner N, Foekens JA.

Clin Cancer Res. 2006 Dec 1;12(23):7054-8. Epub 2006 Nov 17.

18.

Tissue inhibitor of metalloproteinases-1 in breast cancer.

Würtz SØ, Schrohl AS, Sørensen NM, Lademann U, Christensen IJ, Mouridsen H, Brünner N.

Endocr Relat Cancer. 2005 Jun;12(2):215-27. Review.

PMID:
15947098
19.

Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients.

Würtz SØ, Christensen IJ, Schrohl AS, Mouridsen H, Lademann U, Jensen V, Brünner N.

Mol Cell Proteomics. 2005 Apr;4(4):483-91. Epub 2005 Jan 8.

20.

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.

Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brünner N, Foekens JA.

Clin Cancer Res. 2004 Apr 1;10(7):2289-98.

21.

Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay.

Holten-Andersen MN, Schrohl AS, Brünner N, Nielsen HJ, Høgdall CK, Høgdall EV.

Int J Biol Markers. 2003 Jul-Sep;18(3):170-6.

PMID:
14535586
22.

Tumor markers: from laboratory to clinical utility.

Schrohl AS, Holten-Andersen M, Sweep F, Schmitt M, Harbeck N, Foekens J, Brünner N; European Organisation for Research and Treatment of Cancer (EORTC) Receptor and Biomarker Group.

Mol Cell Proteomics. 2003 Jun;2(6):378-87. Epub 2003 Jun 17. Review. No abstract available.

23.

Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.

Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, Foekens JA, Brunner N, Holten-Andersen MN.

Mol Cell Proteomics. 2003 Mar;2(3):164-72. Epub 2003 Apr 2.

Supplemental Content

Loading ...
Support Center